Imprese · 10/11/20261 min di lettura
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention…